pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
789
stories
20d
STAT+: Up and down the ladder: The latest comings and goings
stat
21d
TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms
biospace
21d
STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more
stat
21d
Chai Discovery signs GSK deal to make biologics with AI
endpoints
21d
TRex Bio prices $117M IPO to support immune drug work
biopharma dive
21d
GSK drinks in Chai Discovery’s AI models after wet-lab validation
fiercebiotech
21d
Pfizer pens $500M Enodia pact to join Lilly in emerging protein degrader field
fiercebiotech
21d
TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension
endpoints
21d
Hengrui has become the go-to source of China biopharma innovation. What’s its secret?
fiercebiotech
21d
Lilly-backed TRex rakes in $117M IPO, while hypertension biotech Retension reveals $45M listing
fiercebiotech
21d
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
biospace
21d
Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle
endpoints
22d
Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
biospace
22d
AI biotech Iambic aims for $135M IPO to push cancer drugs through clinic
fiercebiotech
22d
Zealand, Roche’s ‘intriguing’ weight loss for amylin drug soured by blood sugar data
fiercebiotech
22d
Cerevance Parkinson’s drug shortens 'off time' in Ph. 3, paving path to FDA
biospace
23d
Biotech VC Forbion raises record $2.6B to support 30 ‘high-potential’ companies
biospace
23d
STAT+: Justice Department targets drugmakers in new directive on combating white-collar fraud
stat
23d
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
biospace
23d
STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few
stat
23d
STAT+: Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down
stat
23d
5 biggest venture capital raises of Q3 2026
biospace
23d
CAR-T biotech Caribou makes ‘heartbreaking’ call to shrink headcount, halt pipeline
fiercebiotech
23d
Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds
biopharma dive
23d
STAT+: AstraZeneca opens new Boston site
stat
23d
STAT+: Are stem cell treatments about to have their day?
stat
24d
Compliance concerns hinder rollout of AI in drug manufacturing: Survey
biospace
24d
Forbion gets Lilly's backing in Dutch VC's largest-ever fundraising haul
endpoints
24d
The top biopharma conferences in 2027
biopharma dive
24d
Opinion: Why the FDA should not approve an ineffective multicancer screening test
stat
← prev
page 4 of 27
next →
